ATE497949T1 - Tubulininhibitoren - Google Patents

Tubulininhibitoren

Info

Publication number
ATE497949T1
ATE497949T1 AT04801111T AT04801111T ATE497949T1 AT E497949 T1 ATE497949 T1 AT E497949T1 AT 04801111 T AT04801111 T AT 04801111T AT 04801111 T AT04801111 T AT 04801111T AT E497949 T1 ATE497949 T1 AT E497949T1
Authority
AT
Austria
Prior art keywords
tubulin inhibitors
diastereomers
solvates
hydrates
salts
Prior art date
Application number
AT04801111T
Other languages
English (en)
Inventor
Christopher Burns
Andrew Wilks
Michael Harte
Harrison Sikanyika
Emmanuelle Fantino
Colette Sims
Original Assignee
Ym Biosciences Australia Pty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2003906680A external-priority patent/AU2003906680A0/en
Application filed by Ym Biosciences Australia Pty filed Critical Ym Biosciences Australia Pty
Application granted granted Critical
Publication of ATE497949T1 publication Critical patent/ATE497949T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04801111T 2003-12-03 2004-12-03 Tubulininhibitoren ATE497949T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2003906680A AU2003906680A0 (en) 2003-12-03 Tubulin Inhibitors
PCT/AU2004/001689 WO2005054199A1 (en) 2003-12-03 2004-12-03 Tubulin inhibitors

Publications (1)

Publication Number Publication Date
ATE497949T1 true ATE497949T1 (de) 2011-02-15

Family

ID=34637692

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04801111T ATE497949T1 (de) 2003-12-03 2004-12-03 Tubulininhibitoren

Country Status (20)

Country Link
US (5) US7981900B2 (de)
EP (2) EP1689715B1 (de)
JP (2) JP4772690B2 (de)
KR (2) KR101260717B1 (de)
CN (2) CN102127056B (de)
AT (1) ATE497949T1 (de)
AU (1) AU2004294354B2 (de)
BR (1) BRPI0417354A (de)
CA (2) CA2545422C (de)
CY (1) CY1111410T1 (de)
DE (1) DE602004031357D1 (de)
DK (1) DK1689715T3 (de)
ES (2) ES2528302T3 (de)
IL (1) IL175576A (de)
NZ (1) NZ546057A (de)
PL (1) PL1689715T3 (de)
PT (2) PT1689715E (de)
SI (1) SI1689715T1 (de)
WO (1) WO2005054199A1 (de)
ZA (1) ZA200602664B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002953255A0 (en) * 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
NZ546990A (en) 2003-11-20 2010-03-26 Janssen Pharmaceutica Nv 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors
NZ546991A (en) 2003-11-20 2010-01-29 Janssen Pharmaceutica Nv 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors
PT1689715E (pt) 2003-12-03 2011-05-16 Ym Biosciences Australia Pty Inibidores da tubulina
JP5100376B2 (ja) 2004-06-30 2012-12-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体
WO2006003147A1 (en) 2004-06-30 2006-01-12 Janssen Pharmaceutica N.V. Phthalazine derivatives as parp inhibitors
CA2568835C (en) 2004-06-30 2014-05-27 Janssen Pharmaceutica N.V. Quinazolinone derivatives as parp inhibitors
US20090196912A1 (en) * 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
DK1904478T3 (da) * 2005-06-15 2013-09-08 Ym Biosciences Australia Pty Syreadditionssalte af N-ethyl-N'-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea og anvendelser deraf
CA2660560A1 (en) * 2006-08-16 2008-02-21 Boehringer Ingelheim International Gmbh Pyrazine compounds, their use and methods of preparation
DE102006049618A1 (de) * 2006-10-20 2008-05-08 Tschesche, Harald, Prof. Dr. Triazine und Ihre Verwendung als Metalloproteinase-Inhibitoren
AU2013273769B2 (en) * 2006-11-15 2016-05-12 Ym Biosciences Australia Pty Ltd Inhibitors of Kinase Activity
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
JP5545955B2 (ja) 2007-03-08 2014-07-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体
WO2009053373A1 (en) 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
WO2009096198A1 (ja) * 2008-02-01 2009-08-06 Pharma Ip Limited Liability Intermediary Corporations 新規ビアリール誘導体
DK2271626T3 (en) 2008-03-27 2015-02-23 Janssen Pharmaceutica Nv TETRAHYDROPHENANTHRIDINONES AND TETRAHYDROCYCLOPENTAQUINOLINONES AS INHIBITORS OF POLYMERIZATION OF PARP AND TUBULIN
WO2009118384A1 (en) 2008-03-27 2009-10-01 Janssen Pharmaceutica Nv Quinazolinone derivatives as tubulin polymerization inhibitors
CA2723358A1 (en) * 2008-05-05 2009-11-12 Allison B. Reiss Method for improving cardiovascular risk profile of cox inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
CN102203067B (zh) * 2008-08-25 2014-01-15 Irm责任有限公司 Hedgehog通路调节剂
WO2010046780A2 (en) * 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
CN102264737A (zh) * 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
RU2505539C2 (ru) 2008-12-23 2014-01-27 Эбботт Лэборетриз Антивирусные соединения
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
WO2011057805A1 (en) * 2009-11-12 2011-05-19 R&D Biopharmaceuticals Gmbh Tubulin inhibitors
EP2322537A1 (de) * 2009-11-12 2011-05-18 R & D Biopharmaceuticals Gmbh Tubulinhemmer
WO2012174028A2 (en) * 2011-06-13 2012-12-20 The Board Of Trustees Of The University Of Illinois Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion
ME02535B (de) * 2012-02-17 2017-02-20 Univ Cape Town Antimalariamittel
CN102826985B (zh) * 2012-09-18 2015-08-19 厦门大学 一种1-(3,4,5-三羟基)苯基-1-烷基酮的制备方法
JP2016506417A (ja) * 2013-01-10 2016-03-03 プルモキネ、インコーポレイテッド キナーゼ阻害剤の治療指標
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
WO2016167795A1 (en) * 2015-04-17 2016-10-20 Southern Research Institute Treatment of hepatitis b viral
CN106167482A (zh) * 2015-05-19 2016-11-30 重庆大学 一种抑制前列腺癌生长的化合物及其应用
CN107304203A (zh) * 2016-04-20 2017-10-31 苏州苏领生物医药有限公司 五元杂环类化合物及其制备方法、药物组合物和用途
WO2017181974A1 (zh) * 2016-04-20 2017-10-26 苏州苏领生物医药有限公司 五元杂环类化合物及其制备方法、药物组合物和用途
CN106565685B (zh) * 2016-10-11 2019-03-01 深圳海王医药科技研究院有限公司 微管蛋白抑制剂
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
CN111727042A (zh) 2017-12-06 2020-09-29 仁新医药私人有限公司 微管蛋白抑制剂
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
CN108658963A (zh) * 2018-06-20 2018-10-16 桑文军 一种作用于微管蛋白的抗肿瘤药物
IL286902B2 (en) * 2019-04-03 2025-03-01 Aligos Therapeutics Inc Pyrrole compounds
EP4143167B1 (de) 2020-04-28 2024-05-15 Basf Se Pestizidverbindungen
KR20250107752A (ko) * 2024-01-05 2025-07-14 주식회사 큐피크바이오 튜불린 저해제를 포함하는 피부 질환 예방 또는 치료용 조성물
WO2026064527A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload
WO2026064520A1 (en) 2024-09-19 2026-03-26 Tesseract Medicines Us, Llc Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE82928C (de) 1893-06-18 1895-10-01
FR352807A (fr) 1905-03-28 1905-08-22 Julius Schroeder Perfectionnements apportés aux boites à fumée des chaudières à tubes bouilleurs et aux brosses de nettoyage
GB253816A (en) 1925-12-29 1926-06-24 Spencer Bonecourt Ltd Improvements relating to the cleaning of the fire-tubes of a boiler
US3354490A (en) 1964-06-15 1967-11-28 Power Tube Inc Boiler tube cleaning apparatus
CH593266A5 (de) 1973-09-20 1977-11-30 Delalande Sa
US4367790A (en) 1980-12-16 1983-01-11 Draeger Walter A Multiple tube cleaning apparatus
JPS61228296A (ja) 1985-03-30 1986-10-11 Takao Sakamoto 熱交換器における伝熱管の内面洗浄方法
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6147080A (en) 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
AT405973B (de) 1998-06-26 2000-01-25 Hackl Hubert Reinigungsvorrichtung für wärmetauscherzüge
DE19853278A1 (de) * 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
JP2000180093A (ja) 1998-12-15 2000-06-30 Toshiba Plant Kensetsu Co Ltd 熱交換器の管内清掃・探傷検査装置、及び管内清掃・探傷検査方法
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
AU2001278206A1 (en) * 2000-08-08 2002-02-18 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective 2-pyridinamine compositions and related methods
WO2002020495A2 (en) * 2000-09-06 2002-03-14 Chiron Corporation Inhibitors of glycogen synthase kinase 3
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
EP1351691A4 (de) * 2000-12-12 2005-06-22 Cytovia Inc Substituierte 2-aryl-4-arylaminopyrimidine und ihre analoge als aktivatoren von caspasen und apoptoseinduktoren, sowie deren verwendung
WO2002060492A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
MXPA03008888A (es) * 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
WO2003026661A1 (fr) 2001-09-14 2003-04-03 Yamanouchi Pharmaceutical Co., Ltd. Accelerateur de secretion de l'insuline et nouveau derive de pyrimidine
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
CA2486183C (en) * 2002-05-23 2012-01-10 Cytopia Pty Ltd. Protein kinase inhibitors
AU2003232919B2 (en) * 2002-05-23 2009-03-05 Ym Biosciences Australia Pty Ltd Protein kinase inhibitors
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
AU2003249369A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
EP1562911B1 (de) * 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
US7348335B2 (en) * 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
CA2505361A1 (en) * 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
EP1644365A2 (de) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazin- und pyridinderivative als rho-kinase-inhibitoren
EP1648875A1 (de) * 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidine als kinaseinhibitoren
PT1689715E (pt) 2003-12-03 2011-05-16 Ym Biosciences Australia Pty Inibidores da tubulina
DK1904478T3 (da) 2005-06-15 2013-09-08 Ym Biosciences Australia Pty Syreadditionssalte af N-ethyl-N'-[2-methoxy-4-(5-methyl-4-{[(1S)-1-pyridin-3-ylbutyl]amino}pyrimidin-2-yl)phenyl]urea og anvendelser deraf
CA2702647C (en) 2007-01-31 2016-03-22 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof

Also Published As

Publication number Publication date
NZ546057A (en) 2010-04-30
US7981900B2 (en) 2011-07-19
KR20120008078A (ko) 2012-01-25
IL175576A (en) 2012-03-29
JP2011093930A (ja) 2011-05-12
PL1689715T3 (pl) 2011-07-29
EP1689715B1 (de) 2011-02-09
SI1689715T1 (sl) 2011-07-29
ZA200602664B (en) 2007-06-27
DK1689715T3 (da) 2011-05-23
WO2005054199A1 (en) 2005-06-16
AU2004294354A1 (en) 2005-06-16
CA2545422A1 (en) 2005-06-16
US20110269760A1 (en) 2011-11-03
BRPI0417354A (pt) 2007-03-13
KR101260717B1 (ko) 2013-05-09
US20080194583A1 (en) 2008-08-14
KR20060123246A (ko) 2006-12-01
ES2528302T3 (es) 2015-02-06
AU2004294354B2 (en) 2009-02-19
US8394806B2 (en) 2013-03-12
CA2857067C (en) 2016-11-22
JP2007513093A (ja) 2007-05-24
US9139560B2 (en) 2015-09-22
PT1689715E (pt) 2011-05-16
EP2277865B1 (de) 2014-11-12
PT2277865E (pt) 2015-02-05
JP5318126B2 (ja) 2013-10-16
CN1890218A (zh) 2007-01-03
EP2277865A1 (de) 2011-01-26
CA2545422C (en) 2015-06-02
CN102127056A (zh) 2011-07-20
US9732046B2 (en) 2017-08-15
US20160031835A1 (en) 2016-02-04
EP1689715A4 (de) 2008-01-23
CA2857067A1 (en) 2005-06-16
CN1890218B (zh) 2011-08-03
ES2360703T3 (es) 2011-06-08
US20140221396A1 (en) 2014-08-07
US20130274263A1 (en) 2013-10-17
EP1689715A1 (de) 2006-08-16
DE602004031357D1 (de) 2011-03-24
JP4772690B2 (ja) 2011-09-14
CN102127056B (zh) 2013-08-21
CY1111410T1 (el) 2015-08-05
IL175576A0 (en) 2006-09-05
KR101206843B1 (ko) 2012-11-30

Similar Documents

Publication Publication Date Title
DK1689715T3 (da) Tubulininhibitorer
PL378555A1 (pl) Sulfonoamido-podstawione pochodne ksantyny do stosowania jako inhibitory PEPCK
DE60317198D1 (de) Proteinkinaseinhibitoren
ATE457025T1 (de) Kinaseinhibitoren
MY132094A (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
TW200510441A (en) Novel compounds
SG160211A1 (en) Pi-3 kinase inhibitor prodrugs
DK1836201T4 (da) Pyrrolidininhibitorer af IAP.
PT2151250E (pt) Agentes de formação de imagem direccionados para vitamina
TW200504061A (en) Pyrazolopyridine derivatives
CY1114284T1 (el) Σουλφονυλοπυρρολες ως hdac αναστολεις
BR0317715A (pt) Composições e processos de uso de collajolie
CY1106425T1 (el) Ενωσις βενζυλαμινης και φαρμακευτικη χρησις αυτης
NO20005237D0 (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
CY1106471T1 (el) Νεα μεθοδος συνθεσης της περινδροπριλης και των φαρμακευτικως αποδεκτων αλατων αυτης
MXPA02012054A (es) Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.
AP2002002466A0 (en) 3-heterocycliylpropanohydroxamic acid PCP INHIBITORS.
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
TW200506012A (en) Use for the oleo-repellent paper sizing of carboxylic perfluoropolyethers
GB0403148D0 (en) Chemical compounds
MXPA05006957A (es) Nuevos derivados de fosforamida.
EA200600608A1 (ru) Производные имидазопиридина как ингибиторы индуцируемой no-синтазы
EA200600455A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200600456A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей
EA200601086A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1689715

Country of ref document: EP